CYTOKINETICS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Cytokinetics (CYTK) EVP Fady Malik sold 3,500 shares for $239,015 and exercised options for 3,500 more. The company reported $25.3M in Myqorzo sales, beating estimates. Barclays raised its price target to $110. Analysts maintain positive ratings, with targets up to $140.
Cytokinetics Inc (CYTK) Director Robert Landry sold 1,000 shares on 2026-09-15, reducing his holding to 8,184 shares. The sale occurred at $72.13 per share, with the company's market cap at $9.64 billion. Over the past year, Landry sold 2,000 shares and bought none, aligning with a broader trend of 79 insider sells and 0 buys. GuruFocus values CYTK at $220.41, suggesting a possible value trap with a 0.33 price-to-GF-Value ratio.
A trust for Cytokinetics (CYTK) CEO Robert I. Blum filed a Rule 144 notice to sell 97,926 shares, valued at $7.1M, on NASDAQ by September 15, 2026. The shares were acquired as equity compensation between 2024 and 2026.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CYTK (CYTOKINETICS INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CYTK coverage spans financial news, insider activity and technology.
In the last 30 days, CYTK insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($9.6M). The most active reporter was Blum Robert I, President & CEO, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Small insider sell may signal limited confidence but size is modest.
The insider sale suggests limited confidence from management and may pressure the stock lower.
Potential downward pressure on CYTK as insider sells shares.
Large insider sell may signal reduced confidence, potentially pressuring the stock short term.
Insider sale of modest size may slightly pressure the stock but likely limited impact.
AlphAI scores every news story that mentions CYTK with an AI model for sentiment and relevance, and aggregates insider trades from CYTOKINETICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cytokinetics (CYTK) EVP Fady Malik sold 3,500 shares for $239,015 and exercised options for 3,500 more. The company reported $25.3M in Myqorzo sales, beating estimates. Barclays raised its price target to $110. Analysts maintain positive ratings, with targets up to $140.
1 min readCytokinetics Inc (CYTK) Director Robert Landry sold 1,000 shares on 2026-09-15, reducing his holding to 8,184 shares. The sale occurred at $72.13 per share, with the company's market cap at $9.64 billion. Over the past year, Landry sold 2,000 shares and bought none, aligning with a broader trend of 79 insider sells and 0 buys. GuruFocus values CYTK at $220.41, suggesting a possible value trap with a 0.33 price-to-GF-Value ratio.
2 min readA trust for Cytokinetics (CYTK) CEO Robert I. Blum filed a Rule 144 notice to sell 97,926 shares, valued at $7.1M, on NASDAQ by September 15, 2026. The shares were acquired as equity compensation between 2024 and 2026.
1 min readBlum Robert I (President & CEO) sold 97,926 indirectly-held shares of CYTOKINETICS INC (CYTK) at $69.33 ($6.79M total) on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readBlum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $73.44 ($0.55M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readStudies in NEJM and Circulation show aficamten, a drug by Cytokinetics, improved symptoms and exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy (nHCM). The drug also altered heart structure and function, addressing a treatment gap. Long-term effects are under study. Cytokinetics funded the research.
3 min readCytokinetics (CYTK) reported detailed Phase 3 trial results for aficamten, showing efficacy and safety in hypertrophic cardiomyopathy. The company plans to file a supplemental drug application, aiming to expand its cardiology franchise. Cytokinetics has a market cap of $10.3 billion and focuses on muscle-related diseases. Regulatory uncertainty and a small pipeline remain risks.
2 min readCytokinetics Inc (CYTK) Director Robert Landry sold 1,000 shares on 2026-09-11 at $74.66 per share, reducing his holdings to 9,184 shares. The company has a market cap of $10.25 billion. Over the past year, insiders have sold 78 times with no buys. GuruFocus values CYTK at $216.76, classifying it as a 'Possible Value Trap.'
1 min readCantor Fitzgerald reiterated an Overweight rating on Cytokinetics (CYTK), citing strong commercial and regulatory outlooks. The stock has risen 38% over the past year, trading at $73.62 with a $10.23B market cap. Analysts have raised earnings estimates, though profitability is not expected this year. Management expects 50% new prescription share by year-end and potential REMS relaxation. Cytokinetics reported Q2 sales of $25.3M for Myqorzo, exceeding estimates. Barclays and Citizens raised price
2 min readRBC Capital Markets believes Cytokinetics has an advantage in a patent dispute with Bristol-Myers Squibb. The firm's stock is currently trading at $64.05, down 0.56% on the day and 5.71% over 5 days, but up 19.02% year-to-date. The dispute's outcome could impact Cytokinetics' future prospects and valuation.
1 min read